Related Experiment Video
Updated: May 22, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Drug-induced liver disease.
1Department of Transplantation, California Pacific Medical Center, San Francisco, 94115, USA. davernt@sutterhealth.org
Clinics in Liver Disease
|May 1, 2012
Summary
Drug-induced liver injury (DILI), a type of hepatotoxicity, is liver damage from drugs or chemicals. This review guides healthcare professionals through challenging DILI cases, covering over 600 causative agents.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Drug-induced liver injury (DILI), or hepatotoxicity, is a significant adverse drug reaction.
- Over 600 drugs and chemicals are known to cause liver injury.
- Existing reviews often focus on pathogenesis or clinical features.
Purpose of the Study:
- To provide guidance on challenging aspects of DILI for clinicians.
- To offer a comprehensive overview for both novice and experienced hepatologists.
- To address vexing issues in the diagnosis and management of drug-induced liver injury.
Main Methods:
- Literature review of DILI pathogenesis and clinical features.
- Synthesis of information on a wide range of hepatotoxic agents.
- Expert consultation insights on complex DILI cases.
Main Results:
- DILI encompasses a broad spectrum of liver injuries from diverse agents.
- Understanding DILI requires knowledge of drug mechanisms and clinical presentations.
- Management strategies are often tailored to specific drug-induced hepatotoxicity patterns.
Conclusions:
- This article serves as a practical guide for managing DILI.
- It aims to enhance the consultant's ability to navigate complex hepatology cases.
- Effective DILI management requires a multidisciplinary approach and continuous learning.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...